Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology

Chronic Myeloid Leukemia

Arizona

Peoria : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Phoenix : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

California

Duarte : City of Hope

A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR

Duarte : City of Hope

A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy

Duarte : City of Hope

Immune Studies in Chronic Myelogenous Leukemia (CML)

Duarte : City of Hope

SWOG 9007: Cytogenetic Studies In Leukemia Patients

Los Angeles : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Los Angeles : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Santa Rosa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Colorado

Denver : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Connecticut

New Britain : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Delaware

Wilmington : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Florida

Hialeah : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Georgia

Atlanta : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Illinois

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Hines : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Indiana

Beech Grove : Indiana Blood and Marrow Transplantation, LLC

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Louisiana

New Orleans : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Maryland

Baltimore : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Massachusetts

Boston : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Missouri

Saint Louis : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Jersey

Newark : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York

Bronx : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Buffalo : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

East Syracuse : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Rochester : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Stony Brook : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Rhode Island

Providence : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Tennessee

Memphis : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Texas

Houston : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Houston : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Washington

Seattle : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Australia

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Austria

Graz : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Wien : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Bulgaria

Pleven : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Sofia : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Sofia : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Varna : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Canada

Halifax, NS : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Halifax, NS : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

London, ON : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Ottawa, ON : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Toronto, ON : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

China

Hong Kong : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Czech Republic

Olomouc : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Praha : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

France

Lille : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Lyon : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Paris : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Poitiers : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Strasbourg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Germany

Freiburg : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Hannover : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Mainz : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Mainz : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Mannheim : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Mannheim : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Marburg : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Tübingen : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Tübingen : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Hungary

Budapest : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

India

Ahmedabad : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Hyderabad : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Lucknow : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Lucknow : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Trivandrum : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Israel

Haifa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Rehovot : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Italy

Bari : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Bologna : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Pavia : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Pisa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Roma : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Torrette di Ancona : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Udine : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Mexico

Monterrey : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Poland

Warszawa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Russian Federation

Moscow : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Moscow : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

St Petersburg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Slovakia

Banska Bystrica : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Bratislava : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Kosice : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Kosice : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

South Africa

Cape Town : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Durban : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Durban : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Johannesburg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Spain

Barcelona : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Madrid : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Toledo : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Valencia : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Zaragoza : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Taiwan

Taipei : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Thailand

Bangkok : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

United Kingdom

Glasgow : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

London : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia